This is a summary of the European public assessment report (EPAR) for Zonegran. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zonegran.
Therapeutic Indication
### Therapeutic indication Zonegran is indicated as: - monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy; - adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged six years and above.
Therapeutic Area (MeSH)
ATC Code
N03AX15
ATC Item
zonisamide
Pharmacotherapeutic Group
Antiepileptics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| zonisamide | N/A | 唑尼沙胺 |
EMA Name
Zonegran
Medicine Name
Zonegran
Aliases
N/ANo risk management plan link.
